首页> 美国卫生研究院文献>Journal of Clinical and Experimental Hepatology >Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India

【2h】

Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India

机译：直接作用的抗病毒药物对未治疗的HCV肝硬化的治疗对肝纤维化和严重程度的影响：来自印度北部三级护理中心的真实生活经验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background/aimsTreatment of chronic hepatitis C infection with direct-acting antiviral (DAA) drugs has been highly effective, but data regarding benefit in advanced liver disease is relatively scarce in Indian patients. The aim of this study was to determine the effects of DAA in patients with HCV related cirrhosis (compensated/decompensated) who achieved sustained virological response post-therapy at 12 weeks (SVR12).

机译：背景/目的用直接作用抗病毒（DAA）药物治疗慢性丙型肝炎感染非常有效，但印度患者中有关晚期肝病获益的数据相对较少。这项研究的目的是确定DAA对HCV相关性肝硬化（代偿/代偿失调）患者在治疗后12周达到持续病毒学应答（SVR12）的作用。

著录项

期刊名称 Journal of Clinical and Experimental Hepatology
作者
Gaurav Garg; Vinod K. Dixit; Sunit K. Shukla; Sudhir K. Singh; Shivam Sachan; Anurag Tiwari; Vinod K. Yadav; Dawesh P. Yadav;
展开▼
作者单位

展开▼
年(卷),期 2018(8),3
年度 2018
页码 241–249
总页数 9
原文格式 PDF
正文语种
中图分类外科学;
关键词
APRI AST to Platelet Ratio Index; FIB-4 fibrosis-4; CTP Child-Turcotte-Pugh; MELD Na Model for End-Stage Liver Disease sodium;

机译：APRI;AST与血小板比率指数;FIB-4;纤维化-4;CTP;Child-Turcotte-Pugh;MELD Na;终末期肝病钠模型;

相似文献

外文文献
中文文献
专利

1. P1‐095: Virological responses & liver functions in patients with HCV related cirrhosis after treatment with directly acting antivirals (DAAs), a real life experience from a tertiary care center in India [J] . Journal of viral hepatitis. . 2018,第S1期

机译：P1-095：在直接代理抗病毒（DAAS）的治疗后HCV相关肝硬化患者的病毒学反应和肝功能，这是印度大专院第中心的现实生活经验
2. Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia [J] . Ligita Jancoriene, Katazyna Polubenko, Edita Kazenaite, Hepatitis Monthly . 2018,第1期

机译：直接作用抗病毒药物Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir联合或不联合利巴韦林在C型肝炎病毒（HCV）基因型1中感染的未接受过治疗或有治疗经验的患者是否患有肝硬化：立陶宛和拉脱维亚的真实生活
3. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network ActivityLINA cohort) [J] . Gentile Ivan, Scotto Riccardo, Coppola Carmine, Hepatology international . 2019,第1期

机译：用直效抗病毒治疗改善了HCV相关的失代偿性肝硬化患者的临床结果：意大利现实队列的结果（肝脏网络致敏LINA COHORT）
4. Analyzing the Impact of the CMS Guidance on Assuring Access to Hepatitis C Virus (HCV) Drugs on Utilization of Direct-Acting Antiviral (DAA) Agents [D] . Ferrell, Kelli Walker. 2017

机译：分析CMS指南对确保获得丙型肝炎病毒（HCV）药物对直接作用抗病毒（DAA）药物利用的影响
5. Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment [O] . Sun Hee Lee, Hyun Phil Shin, Joung Il Lee 2020

机译：具有直接抗病患者的现实世界单中心体验用于改善慢性丙型肝炎治疗后肝纤维化
6. Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India [O] . Gaurav Garg, Vinod K. Dixit, Sunit K. Shukla, 2018

机译：直接作用抗病毒药物治疗NaïveHCV肝硬化的影响肝病的纤维化和严重程度：北印度北印产中心的现实生活经验

Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅